Mild cognitive impairment in Parkinson's disease: Diagnosis and progression to dementia
Iván Galtier1, Antonieta Nieto1, Jesús N Lorenzo2
1a School of Psychology , University of La Laguna , La Laguna , Tenerife , Spain.
Introduction:
Mild cognitive impairment is common in nondemented Parkinson disease patients (PD-MCI) and is considered as a risk factor for dementia (PDD). Recently, the Movement Disorder Society (MDS) published guidelines for PD-MCI, although the studies available are still limited. The aim of this work was to characterize PD-MCI and its progression to dementia. Moreover, the study variables could be considered as predictors for the progression of cognitive impairment.
Method:
The study included 43 patients with idiopathic PD (mean age = 59.19 years, SD = 9.64) and 20 healthy and neurologically normal controls (mean age = 60.85 years, SD = 12.26). The criteria proposed by the MDS Task Force were applied for the PD-MCI diagnosis. Follow-up assessments were conducted within six to eight years after the diagnosis of PD-MCI.
Results:
The results showed that 60.5% of the patients were diagnosed with PD-MCI when a comprehensive assessment was performed (MDS criteria Level 2), while 23.3% of the patients met MCI criteria when a brief assessment was used (MDS criteria Level 1). Multiple domain impairment was the most frequent impairment (96.2%). A total of 42.3% of PD-MCI patients had dementia in the follow-up study. Logistic regression showed that the Hoehn and Yahr stage and education significantly contributed to the prediction of PD-MCI. Moreover, the Hoehn and Yahr stage and memory domain significantly contributed to the prediction of dementia.
Conclusions:
The results of the study: (a) provide relevant data about the process of validation of the MDS PD-MCI criteria, (b) reinforce the hypothesis that PD-MCI is more frequent than previous studies showed without applying MDS criteria, and (c) confirm that PD-MCI is a risk factor for the onset of dementia. Finally, the study shows that neurological impairment, educational level and memory impairment were predictors for the progression of cognitive impairment.
Insights
Mild cognitive impairment in Parkinson
Area of Science:
- Neurology
- Neuroscience
- Gerontology
Background:
- Mild cognitive impairment (MCI) is prevalent in non-demented Parkinson's disease (PD) patients, serving as a significant risk factor for dementia.
- The Movement Disorder Society (MDS) recently established guidelines for diagnosing PD-MCI, yet research utilizing these criteria remains limited.
- Characterizing PD-MCI and understanding its progression to dementia are crucial for patient management and therapeutic development.
Purpose of the Study:
- To characterize mild cognitive impairment in Parkinson's disease (PD-MCI) using the MDS criteria.
- To assess the progression of PD-MCI to dementia over a six-to-eight-year follow-up period.
- To identify predictors for the progression of cognitive impairment in PD patients.
Main Methods:
- The study enrolled 43 idiopathic Parkinson's disease patients and 20 healthy controls.
- MDS Task Force criteria were applied for PD-MCI diagnosis.
- Follow-up assessments were conducted six to eight years post-diagnosis to evaluate cognitive changes and dementia onset.
Main Results:
- A comprehensive assessment (MDS Level 2) diagnosed PD-MCI in 60.5% of patients, versus 23.3% with a brief assessment (MDS Level 1).
- Multiple cognitive domain impairment was observed in 96.2% of PD-MCI patients.
- Dementia developed in 42.3% of PD-MCI patients during the follow-up period.
Conclusions:
- The study validates the MDS PD-MCI criteria, indicating higher prevalence than previously reported.
- PD-MCI is confirmed as a significant risk factor for the development of dementia in Parkinson's disease.
- Neurological impairment (Hoehn and Yahr stage), education, and memory deficits predict cognitive decline and dementia progression.
Related Concept Videos
Parkinson's Disease: Overview
Dementia
The progression of dementia is generally gradual....
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Neural Regulation


